AbCellera Biologics Inc.
$225,000,000.00 CAD
- Program
- SIF Stream3- Attraction
- Recipient country
- Canada
- Fiscal year
- 2021-2022
- Agreement period
- March 18, 2022 – March 31, 2030
- Reference
- ic:033-2023-2024-Q1-819720
Published purpose
This project builds capabilities for therapeutic antibody development, fortifies early-phase clinical research infrastructure, advances biotech IP for the health and economic benefit of Canadians and enables rapid response to future pandemics.
In plain English AI-generated
This project supports AbCellera Biologics Inc. in building capabilities for therapeutic antibody development, strengthening early-phase clinical research infrastructure, and advancing biotechnology intellectual property for Canadian health and economic benefits, including pandemic preparedness.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.